Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Histone H1S-3 phosphorylation in Ha-ras oncogene-transformed mouse fibroblasts

Abstract

Phosphorylation of linker histone H1S-3 (previously named H1b) and core histone H3 is elevated in mouse fibroblasts transformed with oncogenes or constitutively active mitogen-activated protein kinase (MAPK) kinase (MEK). H1S-3 phosphorylation is the only histone modification known to be dependent upon transcription and replication. Our results show that the increased amounts of phosphorylated H1S-3 in the oncogene Ha-ras-transformed mouse fibroblasts was a consequence of an elevated Cdk2 activity rather than the reduced activity of a H1 phosphatase, which our studies suggest is PP1. Induction of oncogenic ras expression results in an increase in H1S-3 and H3 phosphorylation. However, in contrast to the phosphorylation of H3, which occurred immediately following the onset of Ras expression, there was a lag of several hours before H1S-3 phosphorylation levels increased. We found that there was a transient increase in the levels of p21cip1, which inhibited the H1 kinase activity of Cdk2. Cdk2 activity and H1S-3 phosphorylated levels increased after p21cip1 levels declined. Our studies suggest that persistent activation of the Ras-MAPK signal transduction pathway in oncogene-transformed cells results in deregulated activity of kinases phosphorylating H3 and H1S-3 associated with transcribed genes. The chromatin remodelling actions of these modified histones may result in aberrant gene expression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Bottazzi ME, Zhu X, Bohmer RM, Assoian RK . 1999 J. Cell Biol. 146: 1255–1264

  • Chadee DN, Allis CD, Wright JA, Davie JR . 1997 J. Biol. Chem. 272: 8113–8116

  • Chadee DN, Hendzel MJ, Tylipski CP, Allis CD, Bazett-Jones DP, Wright JA, Davie JR . 1999 J. Biol. Chem. 274: 24914–24920

  • Chadee DN, Taylor WR, Hurta RAR, Allis CD, Wright JA, Davie JR . 1995 J. Biol. Chem. 270: 20098–20105

  • Crissman HA, Gadbois DM, Tobey RA, Bradbury EM . 1991 Proc. Natl. Acad. Sci. USA 88: 7580–7584

  • Egan SE, McClarty GA, Jarolim L, Wright JA, Spiro I, Hager G, Greenberg AH . 1987 Mol. Cell Biol. 7: 830–837

  • Gadbois DM, Crissman HA, Tobey RA, Bradbury EM . 1992a Proc. Natl. Acad. Sci. USA 89: 8626–8630

  • Gadbois DM, Hamaguchi JR, Swank RA, Bradbury EM . 1992b Biochem. Biophys. Res. Commun. 184: 80–85

  • Haliotis T, Trimble W, Chow S, Bull S, Mills G, Girard P, Kuo JF, Hozumi N . 1990 Int. J. Cancer 45: 1177–1183

  • Herrera RE, Chen F, Weinberg RA . 1996 Proc. Natl. Acad. Sci. USA 93: 11510–11515

  • Kivinen L, Tsubari M, Haapajarvi T, Datto MB, Wang XF, Laiho M . 1999 Oncogene 18: 6252–6261

  • Kraemer PM, Bradbury EM . 1993 Exp. Cell Res. 207: 206–210

  • Laitinen J, Sistonen L, Alitalo K, Holtta E . 1990 J. Cell. Biol. 111: 9–17

  • Laitinen J, Sistonen L, Alitalo K, Holtta E . 1994 J. Cell Biochem. 57: 1–11

  • Lee HL, Archer TK . 1998 EMBO J. 17: 1454–1466

  • Lennox RW, Oshima RG, Cohen LH . 1982 J. Biol. Chem. 257: 5183–5189

  • Lu MJ, Dadd CA, Mizzen CA, Perry CA, McLachlan DR, Annunziato AT, Allis CD . 1994 Chromosoma 103: 111–121

  • Mahadevan LC, Willis AC, Barratt MJ . 1991 Cell 65: 775–783

  • Mello MLS, Chambers AF . 1994 Anal. Quant. Cytol. Histol. 16: 2 113–123

  • Parseghian MH, Hamkalo BA . 2001 Biochem. Cell Biol. 79: 289–304

  • Parseghian MH, Newcomb RL, Winokur ST, Hamkalo BA . 2000 Chromosome Res. 8: 405–424

  • Paulson JR, Patzlaff JS, Vallis AJ . 1996 J. Cell Sci. 109: 1437–1447

  • Roovers K, Assoian RK . 2000 BioEssays 22: 818–826

  • Roth SY, Allis CD . 1992 Trends Biochem. Sci. 17: 93–98

  • Strelkov IS, Davie JR . 2002 Cancer Res. 62: 75–78

  • Tan KB, Borun TW, Charpentier R, Cristofalo VJ, Croce CM . 1982 J. Biol. Chem. 257: 5337–5338

  • Taylor WR, Chadee DN, Allis CD, Wright JA, Davie JR . 1995 FEBS Lett. 377: 51–53

  • Tuck AB, Wilson SM, Khokha R, Chambers AF . 1991 J. Natl. Cancer Inst. 83: 485–491

  • Wright JA, Egan SE, Greenberg AH . 1994 Anticancer Res. 10: 1247–1256

Download references

Acknowledgements

This research was supported by a grant from the National Cancer Institute of Canada with funds from the Canadian Cancer Society. A Canadian Institutes of Health Research Senior Scientist to JR Davie is also gratefully acknowledged.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to James R Davie.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chadee, D., Peltier, C. & Davie, J. Histone H1S-3 phosphorylation in Ha-ras oncogene-transformed mouse fibroblasts. Oncogene 21, 8397–8403 (2002). https://doi.org/10.1038/sj.onc.1206029

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206029

Keywords

This article is cited by

Search

Quick links